S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
NASDAQ:NVIV

InVivo Therapeutics Stock Forecast, Price & News

$0.54
-0.04 (-6.87%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.53
▼
$0.61
50-Day Range
$0.50
▼
$0.70
52-Week Range
$0.49
▼
$2.00
Volume
938,859 shs
Average Volume
2.05 million shs
Market Capitalization
$18.59 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.13
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive NVIV News and Ratings via Email

Sign-up to receive the latest news and ratings for InVivo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


InVivo Therapeutics logo

About InVivo Therapeutics

Invivo Therapeutics Holdings Corp. operates as a research and clinical-stage biotechnology company, which engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. Its clinical development program is the Neuro-Spinal Scaffold implant, which is an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord. The company was founded by Joseph P. Vacanti, Frank M. Reynolds, and Robert Langer in January 2005 and is headquartered in Cambridge, MA.

Headlines

InVivo Therapeutics Announces Participation at Upcoming H.C. Wainwright Annual Global Investment Conference
September 9, 2021 |  finance.yahoo.com
InVivo Therapeutics Announces 75% Target Enrollment Achieved for the INSPIRE 2.0 Spinal Cord Injury Study
September 8, 2021 |  finance.yahoo.com
InVivo Therapeutics Holdings Corp Common Stock (NVIV)
August 7, 2021 |  nasdaq.com
InVivo Therapeutics Holdings (NASDAQ:NVIV) Is In A Good Position To Deliver On Growth Plans
July 19, 2021 |  finance.yahoo.com
InVivo Therapeutics Announces FDA Acceptance of Preclinical Module in Support of Company’s Complete HDE Submission
July 13, 2021 |  uk.finance.yahoo.com
InVivo Therapeutics Up After FDA Accepts Preclinical Part of Application
July 13, 2021 |  marketwatch.com
InVivo Therapeutics Urges All Stockholders to Vote at the 2021 Annual Meeting to Be Held on Friday July 16, 2021
July 6, 2021 |  finance.yahoo.com
Is Invivo Therapeutics (NVIV) A Good Stock To Buy Now?
June 14, 2021 |  finance.yahoo.com
Is InVivo Therapeutics Holdings (NASDAQ:NVIV) In A Good Position To Deliver On Growth Plans?
April 29, 2021 |  nasdaq.com
InVivo Therapeutics Announces Presentation at Upcoming M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
March 12, 2021 |  finance.yahoo.com
InVivo Therapeutics Announces Presentation at Upcoming 2021 H.C. Wainwright Global Life Sciences Conference
March 5, 2021 |  finance.yahoo.com
Will InVivo Therapeutics Holdings (NASDAQ:NVIV) Spend Its Cash Wisely?
January 19, 2021 |  finance.yahoo.com
InVivo Therapeutics Holdings
November 25, 2020 |  fool.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NVIV
Previous Symbol
CUSIP
N/A
CIK
1292519
Web
www.invivotherapeutics.com
Phone
(617) 863-5500
Fax
N/A
Employees
6
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.61 per share
Price / Book
0.89

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
$-9.07 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-41.25%
Return on Assets
-37.08%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.64
Quick Ratio
13.10

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
34,265,000
Free Float
34,238,000
Market Cap
$18.59 million
Optionable
Not Optionable

Company Calendar

Last Earnings
11/10/2021
Today
12/01/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/07/2022

MarketRank™

Overall MarketRank™

1.08 out of 5 stars

Medical Sector

1232nd out of 1,392 stocks

Surgical & Medical Instruments Industry

118th out of 127 stocks

Analyst Opinion: 0.0Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -












InVivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions

How has InVivo Therapeutics' stock been impacted by COVID-19?

InVivo Therapeutics' stock was trading at $1.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVIV shares have decreased by 66.1% and is now trading at $0.5425.
View which stocks have been most impacted by COVID-19.

When is InVivo Therapeutics' next earnings date?

InVivo Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for InVivo Therapeutics.

How were InVivo Therapeutics' earnings last quarter?

InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV) issued its quarterly earnings data on Wednesday, November, 10th. The biotechnology company reported ($0.07) earnings per share for the quarter.
View InVivo Therapeutics' earnings history.

When did InVivo Therapeutics' stock split? How did InVivo Therapeutics' stock split work?

InVivo Therapeutics's stock reverse split before market open on Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 11th 2020. An investor that had 100 shares of InVivo Therapeutics stock prior to the reverse split would have 3 shares after the split.

Who are InVivo Therapeutics' key executives?

InVivo Therapeutics' management team includes the following people:
  • Richard Toselli, President, Chief Executive Officer & Director
  • William D'Agostino, Senior Vice President-Operations
  • Richard C. Christopher, Chief Financial Officer & Treasurer
  • Heather Hamel, Secretary, VP-Legal Affairs & Business Development

What other stocks do shareholders of InVivo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InVivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares Preferred and Income Securities ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), Inovio Pharmaceuticals (INO), Apollo Investment (AINV), IVERIC bio (OPHT), OPKO Health (OPK) and Cardiff Oncology (TROV).

What is InVivo Therapeutics' stock symbol?

InVivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV."

Who are InVivo Therapeutics' major shareholders?

InVivo Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Two Sigma Securities LLC (0.13%).
View institutional ownership trends for InVivo Therapeutics.

Which institutional investors are buying InVivo Therapeutics stock?

NVIV stock was bought by a variety of institutional investors in the last quarter, including Two Sigma Securities LLC.
View insider buying and selling activity for InVivo Therapeutics or or view top insider-buying stocks.

How do I buy shares of InVivo Therapeutics?

Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InVivo Therapeutics' stock price today?

One share of NVIV stock can currently be purchased for approximately $0.54.

How much money does InVivo Therapeutics make?

InVivo Therapeutics has a market capitalization of $18.59 million.

How many employees does InVivo Therapeutics have?

InVivo Therapeutics employs 6 workers across the globe.

What is InVivo Therapeutics' official website?

The official website for InVivo Therapeutics is www.invivotherapeutics.com.

Where are InVivo Therapeutics' headquarters?

InVivo Therapeutics is headquartered at ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139.

How can I contact InVivo Therapeutics?

InVivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at (617) 863-5500 or via email at [email protected].


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.